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Abstract: Oral mucositis (OM) remains a major side effect of various cancer therapies, which 
exacts a signiﬁ  cant price in terms of morbidity and cost of care. Efforts aimed at prevention 
and/or therapy of OM have been largely unsuccessful. Few agents have shown efﬁ  cacy, and even 
those were applicable to limited types of patients. The advent of small-molecule targeted agents 
opened new possibilities for intervention in the mucopathogenic processes induced by cancer 
therapies. One of these agents, recombinant human keratinocyte growth factor (KGF), has been 
studied extensively and has shown promising results in reducing chemotherapy induced OM. This 
drug’s effects on stem cell engraftment, graft-versus-host disease and other treatment-induced 
morbidities remain undeﬁ  ned. In this article we evaluate the pre-clinical and clinical evidence 
and discuss the clinical applications of KGF as an adjunct therapeutic agent in oncology.
Keywords: mucositis, cancer, therapy, palifermin
Introduction
In spite of the recent introduction of targeted therapies for malignant diseases, the 
vast majority of antineoplastic agents have a relatively non-speciﬁ  c cytotoxic mode 
of action. Consequently, cancer treatments continue to be characterized by high 
morbidity and mortality. By virtue of their active metabolic and mitotic processes, 
some of the most commonly affected “innocent bystanders” are the hematopoietic 
and gastrointestinal mucosal cells. In the 1990s we witnessed signiﬁ  cant advances in 
prophylaxis and therapy of hematopoietic side effects of toxic cancer drugs through the 
discovery and introduction to market of speciﬁ  c immune cell colony growth factors.1 
These advances led to an effective decrease in severity and duration of immune cyto-
penias and their associated infectious morbidity. An additional consequence was the 
shift in importance of the mucosal side effects, which have now become the limiting 
toxicity in various cancer regimens. Until recently, gastrointestinal mucositis treat-
ment has been considered an unmet need, with most sufferers receiving only palliative 
agents and nutritional support.1–3
The process of aero-digestive tract injury by cytotoxic therapies remains incompletely 
elucidated. The most recent and compelling theory was proposed by Sonis in 20042 and 
is based on observational phenomena in humans and experimental evidence in a hamster 
animal model. This theory contends that the injurious process begins with damage to 
the vasculature and connective tissues underlying the mucosa, which is followed by 
local signal ampliﬁ  cation and release of pro-inﬂ  ammatory cytokines. Resultant vascu-
lar leakage exacerbates the inﬂ  ammation and leads to epithelial destruction followed 
by bacterial colonization of sub-epithelial tissues. As the cytotoxic effects wane with 
drug discontinuation, the wound healing process predominates and restores epithelial 
integrity, albeit a full return to tissue health requires signiﬁ  cantly more time.
Oral mucositis (OM) is relatively common in cancer patients and ranges in incidence 
from close to 100% in some bone marrow transplantation (BMT) myeloablative 
regimens and radiotherapy for head and neck cancer to less than 10% in solid tumors Biologics: Targets & Therapy 2009:3 112
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treated with milder regimens or targeted protocols.3 The 
morbidity of mucositis in affected patients is signiﬁ  cant 
and occurrence of moderate-severe OM has been associated 
with increases in the number of hospital days, parenteral 
nutrition, need for narcotic-based parenteral analgesia and 
mortality.4 The monetary cost of OM has been estimated at 
over US$40,000 per patient afﬂ  icted by ulcerative lesions, 
based on Medicare reimbursement rates. Thus, therapy-
induced OM is far from trivial and recent efforts have been 
directed at ﬁ  nding prophylactic and therapeutic measures. To 
date, relatively few compelling results have been achieved, 
chief among those being the introduction and testing of the 
recombinant keratinocyte growth factor (KGF) palifermin. 
We will now discuss this medication and the evidence of its 
efﬁ  cacy presented in the literature.
Preclinical studies
KGF is an epithelial cell growth factor expressed by ﬁ  bro-
blasts and endothelial cells, typically in response to pro-
inﬂ  ammatory cytokines and hormones.5,6 This cytokine plays 
an important role in regulating epithelial-mesenchymal inter-
actions and in maintaining epithelial integrity.7 Preclinical 
studies have described increased proliferation and decreased 
apoptosis of epithelial cells in response to KGF administra-
tion. Enhanced neovascularization and collagen deposition 
were also noted in a wound healing animal model.8 Generally, 
wound healing in this model was consistently enhanced by 
either topical or systemic KGF and intestinal anastomoses 
healed faster and withstood more tensile force and skin 
wounds resolved in signiﬁ  cantly less time.
The drug palifermin (recombinant human DeltaN23-
KGF, Biovitrum AB Stockholm, Sweden) has gained sci-
entiﬁ  c attention in late 1990s with the publication of animal 
study results indicating efﬁ  cacy in protection of oral and 
intestinal epithelia from negative effects of radiation and 
chemotherapy.9,10 Initial results described protection of the 
gastrointestinal mucosa in mice treated with lethal doses of 
radiation or chemotherapy.9 Animals exposed to KGF had 
lower mortality that was attributed to the mucosal cytopro-
tection. Increasing the optimism, other studies published at 
the same time indicated that KGF had no protective effect 
on human squamous cell carcinoma cell lines exposed to 
ionizing radiation in vitro and in vivo.11
Farrell et al then studied the effect of palifermin on 
mouth mucosa in mice exposed to ionizing radiation and 
described a reversal of the radiation-induced inhibition of cell 
growth in irradiated animals.12 Further, Potten et al studied 
the effect of KGF on mouse tongue mucosa and similarly 
noted a signiﬁ  cant increase in cell proliferation. When 
animals were subsequently exposed to high dose radiation, 
both incidence and duration of ulceration were reduced.13 
Dorr and co-workers14 also exposed mice to radiation and 
observed the effects of KGF applied before, during or after 
exposure. A signiﬁ  cant reduction in incidence of radiation-
induced ulceration was noted for all three protocols. The 
positive effect was most pronounced when KGF was given 
after radiation, suggesting that the mechanism responsible for 
beneﬁ  ts was increase in tissue repair. However, in a subse-
quent report,15 the same team found longer lasting ulceration 
when KGF was administered after the onset of ulceration as 
compared to control irradiated animals. The reason for this 
apparent contradiction has not been elucidated but the authors 
recommended that KGF be administered prior to appearance 
of ulcerative mucositis.
Expanding the area of study, other researchers16 demon-
strated milder forms of graft-vs-host disease (GVHD) after 
chemoradiotherapy conditioning followed by allogeneic 
bone marrow transplantation (BMT) in animals pretreated 
with palifermin. These animals also had enhanced engraft-
ment, presumably by mechanisms independent of the repair 
of cytotoxic-induced tissue injury. One possible explanation 
was presented by Seggewiss et al17 who described improved 
immune reconstitution and thymus preservation in monkeys 
treated with myeloablative radiation and KGF. Finally, a 
group studied the effect of radiation on salivary gland cells 
and saliva production in mice that received palifermin before 
and/or after exposure to the cytotoxic therapy.18 The authors 
concluded that KGF alleviated radiation-induced damage 
to the glands by stimulating growth of the acinar progenitor 
stem cell pool. While radiation sensitivity was not affected, 
the increase in the number of stem cells compensated for 
radiation-induced killing. Gland function measured in vivo 
was also improved.
These animal studies were in accord that palifermin has 
a potential role as a disease modiﬁ  er in radiation-induced 
mucosal injury, immune reconstitution and in GVHD. 
However, other studies created serious doubt about potential 
use of this cytokine for chemotherapy-induced damage.19–21 
A group in Oklahoma19 reported a dose-dependent KGF 
induction of estrogen receptor-positive breast cancer cell 
proliferation and motility, even at very low drug levels. 
Contrary to previous suggestions, these authors concluded 
that KGF inhibition may provide therapeutic beneﬁ  ts for 
treatment of metastatic breast cancer.20 A similar study in 
human endometrial carcinoma cells also showed enhanced 
growth as a result of KGF addition.21Biologics: Targets & Therapy 2009:3 113
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Similar worries were expressed in a recent article, which 
described KGF-induced resistance of cancer cells to speciﬁ  c 
chemotherapeutic agents.22 The authors reported complete 
inhibition of breast cancer and normal epithelial cell killing 
by 5-ﬂ  orouracil (5-FU) when KGF was added to cell culture. 
Further, the inhibitory effect of tamoxifen on breast cancer 
cells was also abrogated by the addition of the cytokine. In 
contrast, another recent study23 tested the effect of combining 
palifermin with various cytotoxic and biologic medications 
on human head and neck and colorectal cancer xenografts 
in mice. Medications tested included 5-FU, cisplatin and 
three targeted agents. This study showed that palifermin 
neither inﬂ  uenced tumor growth, nor interfered with the 
cell killing activity of any of the tested drugs. Further, a 
report by Gibson et al24 showed that KGF administered to 
breast cancer-bearing rats before treatment with metho-
trexate actually enhanced drug-induced apoptosis in both 
normal intestinal and malignant cells. Thus, no protection 
of mucosal tissues was observed but there was a beneﬁ  cial 
effect on the tumor.
An explanation for these contradictory results is not read-
ily apparent. While most experiments that showed enhanced 
tumor growth and inhibition of cytotoxic properties of drugs 
were performed with breast cancer cells,19–22 the malignant 
lines used in the studies that found no interference12,23 were 
of squamous cell and colorectal origins. Nevertheless, all 
tested cell lines were KGF-receptor positive, which implies 
that their behavior should be similar. Further, the former 
studies were performed primarily in cell culture while the 
latter were animal trials. This suggests that effects of KGF 
in vitro may not translate to in vivo results, where other bio-
logical processes may account for a difference in behavior. 
The odd results reported by Gibson et al24 may be due to the 




The initial introduction of palifermin to human trials occurred 
in a phase I/II dose-escalation experiment in head and 
neck cancer patients receiving chemoradiation.25 Chemo-
therapy-naïve patients were treated with 5-FU and cisplatin 
concomitantly with radiotherapy. KGF was administered 
intravenously (20, 40, 60 or 80 μg/kg) to a minimum of 
12 patients per dose. Results from 60 randomized patients 
(46 palifermin, 14 placebo) showed that the drug was toler-
ated relatively well even at the highest dose, with minimal 
side effects consisting mostly of skin ﬂ  ushing, temporary 
elevation of serum lipase and amylase and hypersalivation. 
Duration of severe mucositis and salivary gland toxicity 
were significantly reduced in the patients treated with 
palifermin.
The same group reported the results of a phase II study of 
palifermin in a similar group of patients.26 Randomly assigned 
99 head and neck cancer patients (2:1 palifermin 60 μg/kg or 
placebo once weekly) were assessed for duration of moder-
ate-severe oral mucositis. Results were not statistically differ-
ent for the whole group. However, subgroup analyses showed 
that duration of mucositis was signiﬁ  cantly reduced in those 
patients who received hyperfractionated radiation and pali-
fermin; conversely, duration of mucositis was increased in 
those treated with standard dose radiation and the cytokine. 
Adverse events, tumor response and overall survival were 
similar for the two groups. It is interesting that patients treated 
with hyperfractionated radiation had beneﬁ  t, as this deliv-
ery of radiation is associated with increased acute mucosal 
toxicity. The results of this post-hoc analysis are not easily 
explained and the authors justly conclude that additional 
studies are necessary to determine the efﬁ  cacy of palifermin 
for chemoradiation-induced mucositis. A phase III trial of 
palifermin in head and neck cancer patients has recently 
completed accrual but results are not yet available.
Chemotherapy
A second phase I study was undertaken in colorectal cancer 
patients treated with a 5-FU-based chemotherapy protocol.27 
This was a randomized (2:1) study of 81 patients who 
received palifermin (1, 10, 20, 40, 60 or 80 μg/kg/day) or 
placebo intravenously on days 4 to 8. Unlike the previous 
clinical study, dose-limiting toxicities were found at 60 and 
80 μg/kg. Incidence of severe mucositis was decreased in pal-
ifermin patients, albeit it did not reach statistical signiﬁ  cance 
(p = 0.6). We note that the study was not powered to show 
signiﬁ  cant mucositis effects and the dose of 1 μg/kg may 
have been insufﬁ  cient to produce any effects on mucositis.
A phase II trial was reported only in abstract form.28 
This study established the palifermin dose at 60 μg/kg 
injected intravenously for 3 days before conditioning and 
3 days after marrow transplantation in BMT patients. 
The practice-changing study was a phase III multicenter 
clinical trial that compared oral mucositis in 106 palifermin- 
(60 μg/kg/day for 3 consecutive days before initiation of 
cytotoxic therapy and on days 0, 1, and 2 after transplanta-
tion) vs 106 placebo-treated autologous BMT patients who 
received marrow-ablative chemotherapy for hematologic 
malignancies.29 Severe mucositis was reported in 63% of Biologics: Targets & Therapy 2009:3 114
Barasch et al
the patients in the palifermin group and 98% of the patients 
treated with placebo (p  0.001). Duration of mucositis 
was also reduced by an average of 3 days in the treatment 
group. Incidence of WHO grade IV mucositis was 21% 
with palifermin compared to 62% with placebo (p  0.001). 
Patient-reported symptoms, swallowing, use of narcotic 
analgesia and use of parenteral nutrition coincided with 
the mucositis curve and were signiﬁ  cantly reduced in the 
palifermin-treated patients. General well-being was also 
improved in the treatment group. Reported adverse effects 
were mild to moderate and consisted mostly of skin effects, 
cough and taste alterations. Transient increases in serum 
amylase and lipase were also common but values returned 
to normal soon after treatment discontinuation. Short-term 
disease-free survival was similar in the two groups but 
long-term effects have not been reported. This study was 
funded by the palifermin’s manufacturer and most authors 
had received ﬁ  nancial beneﬁ  ts from the company. Neverthe-
less, the results clearly showed the efﬁ  cacy of the drug in 
reducing therapy-induced mucositis and improving short-
term outcomes in chemoradiotherapy-treated hematologic 
cancer patients.
A similar study published 2 years later30 conﬁ  rmed the 
beneﬁ  ts of palifermin on oral mucositis in BMT populations. 
This was an open-label cohort trial of the drug where patients 
were compared to historic controls and most results paral-
leled those of the Spilberger study.29 However, no beneﬁ  ts 
were found in use of narcotic medication, dietary intake, 
general well-being or time to engraftment for the KGF-treated 
32 patients. This study also did not report long-term follow-up 
or effects of palifermin on GVHD.
Other cancer patient groups have been studied. A report 
by Rosen et al31 described the effects of palifermin in 
metastatic colorectal cancer patients treated with 5-FU and 
leukovorin. Sixty-four patients were randomly assigned 
to KGF or placebo. The authors reported a decrease in 
incidence of severe oral mucositis with palifermin but 
no effect on diarrhea. Interestingly, despite the possible 
interference of KGF with the efﬁ  cacy of 5-FU, the overall 
2-year survival was similar in the two groups. Longer-term 
survival was not reported. Studying a cohort of 10 patients 
with previous high-dose methotrexate-induced severe 
oral mucositis, Schmidt et al32 also reported signiﬁ  cant 
reductions in incidence and duration of severe lesions when 
KGF was administered in subsequent cycles. In this group 
of patients, the incidence of infection was also substan-
tially lower with palifermin treatment. These preliminary 
studies show that KGF can be efﬁ  cacious even outside 
the BMT setting. However, longer follow-up and rigorous 
methodology must be employed in future studies to insure 
that disease recurrence and long-term survival are not 
negatively affected by palifermin.
Results from Spielberger et al study29 were used post-hoc 
to calculate the economic consequences of palifermin in 
BMT patients.33 This analysis was based upon estimated 
Medicare reimbursement and concluded that the price of 
palifermin was easily offset by savings from reduced hospital 
stay and palliative medication. In ﬁ  nal analysis, an average 
non-statistically signiﬁ  cant saving of US$3,595 per patient 
was achieved by using the drug.
GVHD
Following the positive results in animal studies,16 the effect 
of KGF on GVHD became a topic of interest. Three recent 
studies address this issue. Langner et al34 reported the 
results of a muticenter study that enrolled 30 allogeneic 
BMT patients to receive palifermin and compared them to 
matched historic controls. Consistent with previous studies, 
incidence, severity and duration of oral mucositis as well 
as use of narcotic medication and parenteral nutrition were 
signiﬁ  cantly reduced in the palifermin group. However, 
no beneﬁ  ts were seen for the incidence of acute GVHD, 
febrile neutropenia, infectious episodes or hematopoietic 
recovery. Short-term survival was similarly not affected. 
The second study was a randomized trial35 that used higher 
doses of palifermin (240–720 μg/kg) in 100 allogeneic 
BMT patients. Similar to the Langner study, the authors 
reported beneﬁ  cial effects for oral mucositis but not on 
acute GVHD, engraftment or survival. Unlike the previous 
reports, these authors provided long-term follow up data, 
which showed no differences in incidence of infection, 
chronic GVHD or long-term survival. Lastly, the results of a 
multicenter study36 on 53 BMT Polish patients compared to 
53 matched historic controls conﬁ  rmed the positive effects 
of palifermin on severity and duration of mucositis but 
also claimed a signiﬁ  cant reduction in prevalence of acute 
GVHD. This study followed the exact protocol described 
by Spielberger et al.29
The former two studies appear to dim the hope that 
palifermin may be efficacious in reducing GVHD and 
incidence of infection, or provide any beneﬁ  t to engraft-
ment, while the third keeps the ﬂ  ame alive. Nevertheless, 
all studies conﬁ  rm the positive effects of palifermin on 
oral mucositis. Discrepancies in results for use of analgesic 
medication and parenteral nutrition will have to be settled 
in future studies.Biologics: Targets & Therapy 2009:3 115
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Similar medications
The positive results obtained with palifermin encouraged 
investigation of other possible mucositis modulators from 
the same cytokine family. KGF-2 (repifermin) was the ﬁ  rst 
to be studied. In vitro results afﬁ  rmed the lack of effect of the 
drug on 30 carcinoma cell lines, while animal experiments 
conﬁ  rmed no tumor growth activity.37 A phase I/II trial that 
followed also reported encouraging results, with signiﬁ  cant 
reduction of mucositis and no signiﬁ  cant side effects for 
repifermin-treated patients.38 Nevertheless, in February 2004 
the manufacturer announced the abandonment of repifermin 
after an unpublished phase II study did not meet its primary 
end point.
Recombinant fibroblast growth factor (FGF)-20 
(velafermin) is another signaling molecule that may be 
beneﬁ  cial to mucosal cytoprotection. In an hamster model for 
therapy-induced mucositis, administration of intraperitoneal 
velafermin reduced both duration and severity of mucosal 
lesions.39,40 In a phase I open-label human study of FGF-20 in 
30 autologous BMT patients,41 the authors reported no seri-
ous adverse effects. Nevertheless, this drug too was dropped 
in October 2007 when the company reported that FGF-20 
failed to meet its primary endpoint in the management of 
mucositis.
Conclusions
Until recently, cancer therapy-induced oral mucositis was 
considered an unmet need of the oncology patient population. 
With the introduction of palifermin, this paradigm appears 
to have changed, at least for hematopoietic stem cell trans-
plant patients treated with high-dose cytotoxic regimens, 
and perhaps for other cancer patients. Study results from 
well-designed multicenter clinical trials leave little doubt that 
KGF reduces incidence, duration and severity of mucosal 
lesions in the oral cavity. However, whether or not this effect 
translates into a similarly reduced incidence of infection, 
febrile neutropenia and improved nutrition and survival is 
not clear. Similarly, the GVHD beneﬁ  ts observed in animal 
models are not apparent in human studies.
Despite results from two small studies.31,32 the question 
of equivalent efﬁ  cacy of palifermin in other cancer popula-
tions, particularly in those with solid tumors, remains open. 
The reports of stimulated growth and mobility of various 
cancer cell lines by KGF, as well as its potential inhibition 
of cytotoxicity of 5-FU and tamoxifen mandate further 
investigation. Patients with breast cancer as well as those 
treated with regimens containing 5-FU or tamoxifen must 
be approached very cautiously.
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